NCT01710033View on ClinicalTrials.gov

A Study Of CP-690,550 In Stable Kidney Transplant Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Kidney Transplant
Interventions
DRUG

Placebo

Placebo tables twice daily (BID) for 28 days

DRUG

CP-690,550 5 mg BID

CP-690,550 5 mg BID for 28 days

DRUG

CP-690,550 15 mg BID

CP-690,550 15 mg BID for 28 days

DRUG

CP-690,550 30 mg BID

CP-690,550 30 mg BID for 28 days

Trial Locations (11)

35249

Pfizer Investigational Site, Birmingham

46202

Pfizer Investigational Site, Indianapolis

53792

Pfizer Investigational Site, Madison

55404

Pfizer Investigational Site, Minneapolis

90057

Pfizer Investigational Site, Los Angeles

35249-6860

Pfizer Investigational Site, Birmingham

35294-6862

Pfizer Investigational Site, Birmingham

63110-1092

Pfizer Investigational Site, St Louis

63110-1093

Pfizer Investigational Site, St Louis

07039

Pfizer Investigational Site, Livingston

Unknown

Pfizer Investigational Site

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01710033 - A Study Of CP-690,550 In Stable Kidney Transplant Patients | Biotech Hunter | Biotech Hunter